2021
MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT
Shore N, Renzulli J, Fleshner N, Hollowell C, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg M, Tomlins S. MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT. Journal Of Urology 2021, 206: e1099-e1099. DOI: 10.1097/ju.0000000000002102.17.Peer-Reviewed Original Research
2020
A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).
Ross A, Armstrong A, Pieczonka C, Bailen J, Tutrone R, Cooperberg M, Pavlovich C, Renzulli J, Haynes H, Sheikh N, Shore N. A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2020, 38: 321-321. DOI: 10.1200/jco.2020.38.6_suppl.321.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerCD54 upregulationProstate cancerOverall survivalActive surveillanceCell countCastrate-resistant prostate cancerPeripheral blood mononuclear cellsEarly-stage prostate cancerAutologous cellular immunotherapyLarger immune responsesPhase III studyBlood mononuclear cellsStage prostate cancerTotal nucleated cell countNucleated cell countIII studyCellular immunotherapyMononuclear cellsTreatment weekProstate adenocarcinomaT cellsImmune responseTNC countProvent
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply